We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » EMA Clarifies Adverse Events for Off-Label Drug Use
EMA Clarifies Adverse Events for Off-Label Drug Use
Drugmakers are expected to collect individual cases of suspected adverse reactions linked to off-label use but not individual reports when there has been no associated adverse event, the EMA said in April.
To View This Article:
Login
Subscribe To International Pharmaceutical Regulatory Monitor